AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
13.95
14.37
Year Range
4.71
18.61
Daily Change
+0.91%
Monthly Change
-8.19%
6 month change
-2.18%
Year Change
+188.73%
Previous Close
14.2 2
Open
14.0 1
Low
13.9 5
High
14.3 7
Volume
666
Open full chart Full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.6 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-9.39
Price to sales ratio
—

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

News